BWAY Brainsway

BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley

BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley

BURLINGTON, Mass. and JERUSALEM, Sept. 20, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and noninvasive treatment for brain disorders, announced that its President and CEO, Christopher von Jako, PhD, was named an honorary cochair of . The National Alliance on Mental Illness (NAMI) organizes NAMIWalks Your Way events around the country each year to increase mental health awareness, build community, and help raise funds for programs. The Silicon Valley Walk will be Saturday, October 1, 2022.



“I am honored to be part of this extremely important event, which aligns with BrainsWay’s goal of raising awareness about mental illness and increasing access to mental health resources. I am inspired by the work NAMI does for mental health around the country, and I am looking forward to joining forces at the NAMI Silicon Valley walk,” said Dr. von Jako.

He added, “NAMI Walks are wonderful opportunities to meet patients, families, and providers to hear their stories, and work together for a brighter future. I encourage everyone in Silicon Valley to participate in the Walk, taking steps as a community to improve mental healthcare for all.”

Rovina Nimbalkar, Executive Director of NAMI Santa Clara County, said, “We are honored to have Christopher von Jako as our honorary chair for NAMIWalks Silicon Valley and we are excited about our collaboration with BrainsWay. NAMIWalks Silicon Valley is our biggest fundraiser, and after two years we are going to walk in person. The last two years have been particularly difficult for people with a mental health diagnosis, and we walk to honor them and to create awareness for mental illness.”

The October 1 event will be in San Jose’s History Park from 9:00am – 1:00pm PST. In addition to Dr. von Jako, members of the mental health team of the San Francisco Giants will speak at the event, including Drew Robinson, Dr. Emily Payette, Minor League Mental Health Coordinator, and Dr. Shana Alexander, Director of Mental Health, Wellness, and EAP. NAMI is the nation’s largest grassroots mental health organization dedicated to building better lives for the millions of Americans affected by mental illness.

Click to register for the event.



About BrainsWay

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit .

Media Contact:

Meghan Laska

610-212-0125

 

Investors:

Bob Yedid

LifeSci Advisors

646-597-6989



EN
20/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Brainsway

 PRESS RELEASE

BrainsWay Reports Second Quarter 2025 Financial Results and Operationa...

BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights Achieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.5 million, Raised full-year 2025 Revenue and EBITDA guidance Remaining performance obligations increased by 25% YOY to $62 million Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in ad...

 PRESS RELEASE

BrainsWay Champions TMS Education with Sponsorship of Two Free CME Cou...

BrainsWay Champions TMS Education with Sponsorship of Two Free CME Courses for Mental Health Professionals BURLINGTON, Mass. and JERUSALEM, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- , a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, is proud to announce its underwriting of two new designed to expand clinician knowledge and confidence in the use of . These online, no-cost CME activities aim to deepen understanding of the robust clinical evidence supporting TMS, clarify distinctions between Deep TMS™—a proprietary BrainsWay technology—and fir...

 PRESS RELEASE

BrainsWay to Report Second Quarter 2025 Financial Results on August 13...

BrainsWay to Report Second Quarter 2025 Financial Results on August 13, 2025 BURLINGTON, Mass. and JERUSALEM, July 30, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its second quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Wednesday, August 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the res...

 PRESS RELEASE

BrainsWay Reports Positive Results from Multicenter Randomized Study o...

BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD) Improvement in depression scores, response and remission were all found to be comparable with standard Deep TMS in non-inferiority trial BURLINGTON, Mass. and JERUSALEM, June 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced preliminary results from a multicenter, randomized controlled trial titled, “Accelerated Deep TMS for Depress...

 PRESS RELEASE

BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society ...

BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego Deep TMS Takes Center Stage with Compelling Research BURLINGTON, Mass. and JERUSALEM, June 10, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, proudly announces its Gold Sponsorship of the Clinical TMS Society’s 2025 Annual Meeting, taking place June 12–14 in San Diego, CA. BrainsWay’s participation will spotlight its industry-leading Deep Transcranial Magnetic Stimulation (Deep T...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch